REG - PureTech Health PLC - Director Declaration

Puretech HealthAnnouncement

20/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240620:nRST1552Ta&default-theme=true

RNS Number : 1552T  PureTech Health PLC  20 June 2024

20 June 2024

PureTech Health plc

 

PureTech Announces Change of Board Role

 

Raju Kucherlapati, PhD, distinguished Professor of Medicine at Harvard Medical
School, has transitioned to the role of Chair of the Board of Directors on a
permanent basis

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company
dedicated to changing the lives of patients with devastating diseases, today
announces that Raju Kucherlapati, PhD, has been appointed Chair of the Board
of Directors, effective immediately, following his role as interim Chair since
June 2023.

 

"On behalf of the Board, I am delighted to welcome Raju as the Chair on a
permanent basis," said Bharatt Chowrira, PhD, JD, Chief Executive Officer of
PureTech. "Raju's exceptional leadership and strategic vision have been
instrumental to PureTech's innovation and success, particularly over the last
year while he served as interim Chair. The Board has carefully considered
Raju's skills, knowledge and expertise, as well as his long-term involvement
in the evolution of PureTech and his exemplary leadership during his tenure as
interim Chair. The Board determined that Raju's skills and in-depth knowledge
of PureTech will be valuable over the coming years as PureTech continues to
grow and evolve. Raju continues to exercise objective judgement and promote
constructive challenge in the Board's decision-making process. I look forward
to continuing to work together and benefitting from Raju's wise counsel as
PureTech enters an exciting period of growth, with multiple catalysts that can
deliver value to patients and shareholders."

 

Dr. Kucherlapati commented: "It has been an honor to serve as interim Chair of
PureTech at such an exciting time for the business. The Company successfully
delivered against its milestones in 2023 and remains dedicated to identifying
and developing medicines with the potential to transform lives. I look forward
to continuing in my role as Chair and leveraging my expertise, alongside the
rest of the Board, to guide the Company going forward."

 

Dr. Kucherlapati has served as a member of PureTech's Board of Directors since
2014. He is currently Chair of the Board's Nomination Committee and sits on
the Audit and Remuneration Committees. Dr. Kucherlapati will continue his
current Board committee responsibilities until a replacement is identified at
an appropriate time. The Company is actively engaged in a search to expand its
independent Board membership and has had several promising conversations. An
update will be provided in due course.

 

Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of
Medicine at Harvard Medical School and currently serves on the Board of
Directors of KEW Inc. He was a founder and formerly a board member of Abgenix
(acquired by Amgen for $2.2 billion), Cell Genesys and Millennium
Pharmaceuticals (acquired by Takeda for $8.8 billion). He was the first
scientific director of the Harvard-Partners Center for Genetics and Genomics.
He is a fellow of the American Association for the Advancement of Science and
a member of the National Academy of Medicine. Dr. Kucherlapati received his
PhD from the University of Illinois. He trained at Yale and has held faculty
positions at Princeton University, University of Illinois College of Medicine
and the Albert Einstein College of Medicine. He was a member of the
presidential commission for the study of bioethical issues during the Obama
administration.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com) or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to Seaport's development plans and
our future prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to known and
unknown risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially from current
expectations, including, but not limited to, those risks, uncertainties and
other important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2023, filed with
the SEC and in our other regulatory filings. These forward-looking statements
are based on assumptions regarding the present and future business strategies
of the Company and the environment in which it will operate in the future.
Each forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we disclaim
any obligation to update or revise these forward-looking statements, whether
as a result of new information, future events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

 

US Media

Nichole Bobbyn

+1 774 278 8273

nichole@tenbridgecommunications.com
(mailto:nichole@tenbridgecommunications.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNEAEKEAEKLEEA